Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baminercept in Primary Sjögren's Syndrome
NCT01552681Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2012
- Primary completion
- Jan 2015
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary Sjögren's syndrome comparing Baminercept with Placebo (2 arms). Primary endpoint: Change From Screening in Stimulated Whole Salivary Flow at Week 24. Started Jul 2012; status: terminated.
02
Drugs
baminercept
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT01552681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01552681.